Disease Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population nork Negar Molazadeh, Mohammad ali Sahraian, Mahsa Ghajarzadeh

Testu osoa

Predictors of Catching COVID-19 Infection during Pandemic Stage in Patients with Multiple Sclerosis (MS) nork Mahsa Ghajarzadeh, Omid Mirmosayyeb, Negar Molazadeh, Mohammad Ali Sahraian, Simona Bonavita, Vahid Shaygannejad

Testu osoa

Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis nork Evan Madill, Brian C. Healy, Negar Molazadeh, Mariann Polgar‐Turcsanyi, Bonnie I. Glanz, Howard L. Weiner, Tanuja Chitnis

Testu osoa

Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) nork Itay Lotan, Gabriela Romanow, Rebecca Salky, Negar Molazadeh, Anastasia Vishnevetsky, Monique Anderson, Philippe Antoine Bilodeau, Gary Cutter, Michael Levy

Testu osoa